AIAISci
中文
clinical updateBiotech

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Clinical/translation signal: Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Occurred SourceClinicalTrials.govapprovedSourceClinicalTrials.gov

Factual summary

What happened

ClinicalTrials.gov registry update for Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

SourceClinicalTrials.gov

Why it matters

Clinical trial registry updates are translation signals, not commercialization claims by themselves.

SourceClinicalTrials.gov

Limitations

ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.

SourceClinicalTrials.gov

Linked output

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgeryclinical trial

People

No reviewed person relationship is attached to this event.

Organizations

National Cancer Institute (NCI)

Topics

No reviewed topic relationship is attached to this event.

Problems

No reviewed problem relationship is attached to this event.

Relationship evidence

Timeline

  1. clinical updateTesting the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
    SourceClinicalTrials.gov